These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24277659)

  • 21. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
    Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
    J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.
    Gangemi S; Allegra A; Pace E; Alonci A; Ferraro M; Petrungaro A; Saitta S; Gerace D; Russo S; Penna G; Musolino C
    Cell Immunol; 2012; 278(1-2):91-4. PubMed ID: 23121980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.
    Ferdowsi S; Atarodi K; Amirizadeh N; Toogeh G; Azarkeivan A; Shirkoohi R; Faranoush M; Vaezi M; Alimoghaddam K; Ghavamzadeh A; Naghadeh HT; Ghaffari SH
    Int J Lab Hematol; 2015 Oct; 37(5):661-7. PubMed ID: 26011312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts.
    Iizuka K; Morishita S; Nishizaki Y; Iizuka Y; Iriyama N; Ochiai T; Yanagisawa N; Yasuda H; Ando J; Gotoh A; Takei M; Hatta Y; Nakamura H; Nakayama T; Komatsu N
    Eur J Haematol; 2022 Dec; 109(6):779-786. PubMed ID: 36130908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
    Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinguishing essential thrombocythemia
    Silver RT; Krichevsky S
    Haematologica; 2019 Nov; 104(11):2200-2205. PubMed ID: 30948488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
    Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
    Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
    Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
    Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
    Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
    Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Impact of
    Yönal-Hindilerden İ; Şahin E; Hindilerden F; Dağlar-Aday A; Nalçacı M
    Turk J Haematol; 2023 Aug; 40(3):174-182. PubMed ID: 37584526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.
    Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Villamor N; Colomer D; Cervantes F
    Haematologica; 2006 Feb; 91(2):169-75. PubMed ID: 16461300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.
    Gangaraju R; Song J; Kim SJ; Tashi T; Reeves BN; Sundar KM; Thiagarajan P; Prchal JT
    Blood Adv; 2020 Mar; 4(6):1115-1130. PubMed ID: 32203583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
    Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
    Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia.
    Maugeri N; Malato S; Femia EA; Pugliano M; Campana L; Lunghi F; Rovere-Querini P; Lussana F; Podda G; Cattaneo M; Ciceri F; Manfredi AA
    Blood; 2011 Sep; 118(12):3359-66. PubMed ID: 21705500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.